Impact Factor 3.831
2017 JCR, Clarivate Analytics 2018

Frontiers journals are at the top of citation and impact metrics

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2019.00287

A Computational Model of Tumour Growth and Anakoinosis

 Pan Pantziarka1, 2*,  Lina Ghibelli3 and Albrecht Reichle4
  • 1Anticancer Fund, Belgium
  • 2The George Pantziarka TP53 Trust, United Kingdom
  • 3Department of Biology, University of Rome Tor Vergata, Italy
  • 4Klinik und Poliklinik für Innere Medizin III, Universitätsklinikums Regensburg, Germany

Anakoinosis is a new cancer treatment paradigm that posits a key role for communicative reprogramming within tumour systems. To date no mathematical or computational models of anakoinosis have been developed. Here we outline the NEATG_A system, a first computational model of communicative reprogramming. The model recapitulates key features of real tumour systems and responses to both traditional cytotoxic treatments and biomodulatory/anakoinotic treatments. Results are presented and discussed, particularly with respect to the implications for future cancer treatment protocols.

Keywords: Anakoinosis, computational model, Cancer, drug repurposing, Biomodulatory therapy

Received: 11 Oct 2018; Accepted: 08 Mar 2019.

Edited by:

Salvatore Salomone, Università degli Studi di Catania, Italy

Reviewed by:

Parvin Mehdipour, Tehran University of Medical Sciences, Iran
Fabrizio Ferrè, University of Bologna, Italy  

Copyright: © 2019 Pantziarka, Ghibelli and Reichle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Pan Pantziarka, Anticancer Fund, Brussels, Belgium,